DDrare: Database of Drug Development for Rare Diseases

Searched query = "Cushing disease", "Cushing"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE; (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE; 17beta-hydroxy-11beta-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one; 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one; 18F-DOPA; 1H-Pyrazol; 2S,4R-(-)-ketoconazole; 2S,4R-(-)-ketoconazole, levoketoconazole; ATR-101; AZD4017; AZD4017 and prednisolone; Abiraterone; Abiraterone Acetate; Acetate; Acthrel; Bexarotene; CABERGOLINE; CABERGOLINE TEVA; CI-984; CIALIS - 20 MG 2 COMPRESSE RIVESTITE CON FILM IN BLISTER USO ORALE; COR-003; CORT125134; Cabergoline; Calcium; Calcium carbonate; Carbonate; Corticotropin; Corticotropin-releasing hormone; Cushing's syndrome confirmation; Cyclo ((diaminoethyl-carbamate)HyPro-Phg-(D) Trp-Ly di-aspartate; Cyclo ((diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Ly di-aspartate; Cyclo((diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Lys-Tyr(Bzl)-Phe) di-aspartate; Cyclo(diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Lys-Tyr(Bzl)-Phe); DDAVP; DOSTINEX; Device: IPC; Device: continuous glucose monitoring; Dexamethasone; Diagnostic Test: 24-hour Urine test; Diagnostic Test: Blood test; Diagnostic Test: CT scan; Diagnostic Test: Dexamethasone test; Diagnostic Test: MRI; Diagnostic Test: Saliva swab; Dostinex; Dotatate; Eplerenone; Gefitinib; Genotropin 12mg; Genotropin 5.3mg; Genotropin Miniqu; Genotropin Miniquick 0.2mg; Genotropin Miniquick 0.4mg; Genotropin Miniquick 0.6mg; Genotropin Miniquick 0.8mg; Genotropin Miniquick 1.0mg; Genotropin Miniquick 1.2mg; Glucocorticoids; Glucophage (metformin); Glucose; HRA052015; HRA052015 (mifepristone); Hydrocortisone; Hypro; Insulin; KETOCONAZOLE; Ketoconazole; L0006CP03A; LA; LCI699; LCI699, 1 mg; LCI699, 10 mg; LCI699, 20 mg; LCI699, 5 mg; LMWH/Rivaroxaban; Lapatinib; Levoketoconazole; Levoketozonazole; Liqourice; Liraglutide; METYRAPONE; MIFEPRISTONE; Matyrapone; Metformin; Methionine; Metopirone; Metopirone 250 mg capsules; Metopirone 250 mg capsules/Cormeto; Metyrapone; Mifedren; Mifepristone; NIZORAL; Nevanimibe; Nevanimibe hydrochloride; Nizoral; OROCAL; OSILODROSTAT; OSTEOPOR; Octreotide; Osilodrostat; Osilodrostat 10mg; Osilodrostat 1mg; Osilodrostat 20mg; Osilodrostat 5mg; Ossein hydroxyapatite; Other: Control; Other: Hydrocortisone; Other: Obese; Other: [11C]-Methionine PET/MRI; Ovine Corticotropin-Releasing Hormone (oCRH); PASIREOTIDE; PASIREOTIDE DIASPARTATE; PASIREOTIDE PAMOATE; Pasireotida; Pasireotida 300; Pasireotida 600; Pasireotida 900; Pasireotide; Pasireotide 0.3mg; Pasireotide 0.6 MG/ML; Pasireotide 0.6mg; Pasireotide 0.9 mg; Pasireotide 20mg; Pasireotide 40mg; Pasireotide 60mg; Pasireotide LAR; Pasireotide pamoate; Pasireotide s.c.; Pasireotide sub-cutaneous; Pasireotide with or without cabergoline; Pasireotode; Pentetreotide; Phe; Prednisolone; Procedure: Hypercortisolism; Procedure: Lateral transperitoneal LA; Procedure: Posterior RA; R-roscovitine; RVG 08938; RVG 15375; RVG 18236; Radiation: DOTATATE PET-CT; Radiation: F-DOPA PET CT; Relacorilant; Rivaroxaban; Rosiglitazone; Rosiglitazone maleate; SIGNIFOR; SOM230; SOM230 300µg; SOM230 600µg; SOM230 900µg; SOM230 LAR; SOM230 LAR 10 mg; SOM230 LAR 30 mg; SOM230 LAR, 20 mg; SOM230 s.c.; SOM230, 300micrograms; SOM230, 600 micrograms; SOM230, 900 micrograms; SOM230B; SOMATROPIN; Seliciclib; Signifor; Sitagliptin; Somatropin; Tadalafil; Tretinoin; Trp; Tyr; Valsartan; Vorinostat

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-004647-20-NL (EUCTR)	29/08/2019	23/11/2018	A Study to Assess Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome	An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome	Endogenous Cushing´s syndrome (CS) MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Product Name: levoketoconazole Product Code: COR-003 INN or Proposed INN: levoketozonazole	Cortendo AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 3	France;United States;Hungary;Greece;Poland;Spain;Romania;Israel;Bulgaria;Netherlands;Italy
2	EUCTR2017-004647-20-GR (EUCTR)	21/03/2019	19/02/2019	A Study to Assess Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome	An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome	Endogenous Cushing´s syndrome (CS) MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Product Name: levoketoconazole Product Code: COR-003 INN or Proposed INN: levoketozonazole	Cortendo AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 3	United States;France;Hungary;Greece;Spain;Poland;Romania;Denmark;Israel;Bulgaria;Netherlands;Italy
3	EUCTR2017-004647-20-BG (EUCTR)	11/02/2019	24/10/2018	A Study to Assess Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome	An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome	Endogenous Cushing´s syndrome (CS) MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Product Name: levoketoconazole Product Code: COR-003 INN or Proposed INN: levoketozonazole	Cortendo AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 3	France;United States;Hungary;Greece;Poland;Spain;Romania;Denmark;Israel;Bulgaria;Netherlands;Italy
4	EUCTR2017-004647-20-HU (EUCTR)	13/11/2018	26/09/2018	A Study to Assess Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome	An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome	Endogenous Cushing´s syndrome (CS) MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Product Name: levoketoconazole Product Code: COR-003 INN or Proposed INN: levoketozonazole	Cortendo AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 3	Hungary;Poland;Romania;United States;Greece;Spain;Turkey;Israel;Italy;France;Denmark;Bulgaria;Netherlands
5	EUCTR2017-001219-35-FR (EUCTR)	23/05/2018	24/10/2017	A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome	A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome	Endogenous Cushing´s syndrome (CS) MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]	Product Name: levoketoconazole Product Code: COR-003 INN or Proposed INN: levoketozonazole	Cortendo AB	NULL	Not Recruiting			Female: yes Male: yes	35	Phase 3	United States;Greece;Spain;Israel;Italy;France;Hungary;Canada;Poland;Romania;Denmark;Bulgaria;Netherlands
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	EUCTR2017-001219-35-GR (EUCTR)	08/05/2018	04/04/2018	A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome	A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome	Endogenous Cushing´s syndrome (CS) MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]	Product Name: levoketoconazole Product Code: COR-003 INN or Proposed INN: levoketozonazole	Cortendo AB	NULL	Not Recruiting			Female: yes Male: yes	54	Phase 3	United States;France;Hungary;Greece;Spain;Poland;Romania;Denmark;Israel;Bulgaria;Netherlands;Italy
7	EUCTR2017-001219-35-DK (EUCTR)	14/02/2018	19/12/2017	A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome	A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome	Endogenous Cushing´s syndrome (CS) MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]	Product Name: levoketoconazole Product Code: COR-003 INN or Proposed INN: levoketozonazole	Cortendo AB	NULL	Not Recruiting			Female: yes Male: yes	35	Phase 3	United States;France;Hungary;Greece;Spain;Poland;Romania;Denmark;Israel;Bulgaria;Netherlands;Italy
8	EUCTR2017-001219-35-BG (EUCTR)	23/01/2018	30/10/2017	A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome	A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome	Endogenous Cushing´s syndrome (CS) MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]	Product Name: levoketoconazole Product Code: COR-003 INN or Proposed INN: levoketozonazole	Cortendo AB	NULL	Not Recruiting			Female: yes Male: yes	54	Phase 3	United States;France;Hungary;Greece;Spain;Poland;Romania;Denmark;Israel;Bulgaria;Netherlands;Italy
9	EUCTR2017-001219-35-ES (EUCTR)	22/01/2018	17/10/2017	A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome	A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome	Endogenous Cushing´s syndrome (CS) MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]	Product Name: levoketoconazole Product Code: COR-003 INN or Proposed INN: levoketozonazole	Cortendo AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 3	United States;Greece;Spain;Israel;Italy;France;Hungary;Canada;Poland;Romania;Denmark;Bulgaria;Netherlands
10	EUCTR2017-001219-35-PL (EUCTR)	16/01/2018	28/11/2017	A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome	A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome	Endogenous Cushing´s syndrome (CS) MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]	Product Name: levoketoconazole Product Code: COR-003 INN or Proposed INN: levoketozonazole	Cortendo AB	NULL	Not Recruiting			Female: yes Male: yes	54	Phase 3	United States;France;Hungary;Greece;Spain;Poland;Romania;Denmark;Israel;Bulgaria;Netherlands;Italy
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
11	EUCTR2017-001219-35-HU (EUCTR)	12/01/2018	16/11/2017	A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome	A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome	Endogenous Cushing´s syndrome (CS) MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]	Product Name: levoketoconazole Product Code: COR-003 INN or Proposed INN: levoketozonazole	Cortendo AB	NULL	Not Recruiting			Female: yes Male: yes	35	Phase 3	United States;France;Hungary;Greece;Spain;Poland;Romania;Denmark;Israel;Bulgaria;Netherlands;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2017-004647-20-NL
(EUCTR)

29/08/2019

23/11/2018

A Study to Assess Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome

An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome

Endogenous Cushing´s syndrome (CS)
MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]

Product Name: levoketoconazole
Product Code: COR-003
INN or Proposed INN: levoketozonazole

Cortendo AB

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 3

France;United States;Hungary;Greece;Poland;Spain;Romania;Israel;Bulgaria;Netherlands;Italy

EUCTR2017-004647-20-GR
(EUCTR)

21/03/2019

19/02/2019

A Study to Assess Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome

An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome

Product Name: levoketoconazole
Product Code: COR-003
INN or Proposed INN: levoketozonazole

Cortendo AB

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 3

United States;France;Hungary;Greece;Spain;Poland;Romania;Denmark;Israel;Bulgaria;Netherlands;Italy

EUCTR2017-004647-20-BG
(EUCTR)

11/02/2019

24/10/2018

A Study to Assess Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome

An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome

Product Name: levoketoconazole
Product Code: COR-003
INN or Proposed INN: levoketozonazole

Cortendo AB

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 3

France;United States;Hungary;Greece;Poland;Spain;Romania;Denmark;Israel;Bulgaria;Netherlands;Italy

EUCTR2017-004647-20-HU
(EUCTR)

13/11/2018

26/09/2018

A Study to Assess Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome

An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome

Product Name: levoketoconazole
Product Code: COR-003
INN or Proposed INN: levoketozonazole

Cortendo AB

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 3

Hungary;Poland;Romania;United States;Greece;Spain;Turkey;Israel;Italy;France;Denmark;Bulgaria;Netherlands

EUCTR2017-001219-35-FR
(EUCTR)

23/05/2018

24/10/2017

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome

A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome

Product Name: levoketoconazole
Product Code: COR-003
INN or Proposed INN: levoketozonazole

Cortendo AB

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

United States;Greece;Spain;Israel;Italy;France;Hungary;Canada;Poland;Romania;Denmark;Bulgaria;Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2017-001219-35-GR
(EUCTR)

08/05/2018

04/04/2018

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome

Product Name: levoketoconazole
Product Code: COR-003
INN or Proposed INN: levoketozonazole

Cortendo AB

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

United States;France;Hungary;Greece;Spain;Poland;Romania;Denmark;Israel;Bulgaria;Netherlands;Italy

EUCTR2017-001219-35-DK
(EUCTR)

14/02/2018

19/12/2017

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome

Product Name: levoketoconazole
Product Code: COR-003
INN or Proposed INN: levoketozonazole

Cortendo AB

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

United States;France;Hungary;Greece;Spain;Poland;Romania;Denmark;Israel;Bulgaria;Netherlands;Italy

EUCTR2017-001219-35-BG
(EUCTR)

23/01/2018

30/10/2017

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome

Product Name: levoketoconazole
Product Code: COR-003
INN or Proposed INN: levoketozonazole

Cortendo AB

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

United States;France;Hungary;Greece;Spain;Poland;Romania;Denmark;Israel;Bulgaria;Netherlands;Italy

EUCTR2017-001219-35-ES
(EUCTR)

22/01/2018

17/10/2017

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome

Product Name: levoketoconazole
Product Code: COR-003
INN or Proposed INN: levoketozonazole

Cortendo AB

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 3

United States;Greece;Spain;Israel;Italy;France;Hungary;Canada;Poland;Romania;Denmark;Bulgaria;Netherlands

EUCTR2017-001219-35-PL
(EUCTR)

16/01/2018

28/11/2017

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome

Product Name: levoketoconazole
Product Code: COR-003
INN or Proposed INN: levoketozonazole

Cortendo AB

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

United States;France;Hungary;Greece;Spain;Poland;Romania;Denmark;Israel;Bulgaria;Netherlands;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2017-001219-35-HU
(EUCTR)

12/01/2018

16/11/2017

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome

Product Name: levoketoconazole
Product Code: COR-003
INN or Proposed INN: levoketozonazole

Cortendo AB

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

United States;France;Hungary;Greece;Spain;Poland;Romania;Denmark;Israel;Bulgaria;Netherlands;Italy